Biogen halts vixotrigine development in painful lumbosacral radiculopathy
Biogen Inc. (NASDAQ:BIIB) will halt development of vixotrigine (BIIB074) for a pain indication after a Phase IIb miss disclosed in the biotech's 3Q18 earnings. Biogen beat total revenue and earnings estimates for the quarter, with higher-than-expected sales of spinal muscular atrophy (SMA) drug Spinraza nusinersen. The news comes just ahead of this week's Clinical Trials on Alzheimer's Disease (CTAD) meeting in Barcelona, which will feature data for Alzheimer's disease candidate BAN2401.
Biogen will end its vixotrigine program in painful lumbosacral radiculopathy after the therapy missed primary and secondary efficacy endpoints in a Phase IIb trial for the indication. Biogen will postpone Phase III trials in trigeminal neuralgia as it discusses trial design and Phase II data with FDA. Biogen recorded resulting impairment charges of $189 million in 3Q18...